Literature DB >> 9680373

B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity.

H Zhao1, N Dugas, C Mathiot, A Delmer, B Dugas, F Sigaux, J P Kolb.   

Abstract

The expression of different isoforms of nitric oxide synthase (NOS) was investigated in B-cell chronic lymphocytic leukemia (B-CLL) to delineate a possible role for nitric oxide (NO) in the control of apoptosis of the tumoral cells. By reverse transcription-polymerase chain reaction (RT-PCR), all B-CLL cells were found to express spontaneously inducible NOS (iNOS) mRNA, whereas endothelial constitutive NOS (ecNOS) mRNA was undetectable. The iNOS protein was detected by immunofluorescence in the cytoplasm of permeabilized leukemic cells and identified by Western blotting, using different anti-iNOS antibodies, as a protein of 135 kD in B-CLL cytoplasmic extracts. B-CLL cell lysates also displayed basal NOS enzymatic activity, as measured by the conversion of 14C-labeled L-arginine into 14C-L-citrulline. Ligation of CD23, expressed on the vast majority of B-CLL cells, resulted in increased iNOS expression and activity. The NO released exerted an anti-apoptotic effect on B-CLL cells that was counteracted by NOS inhibitors and engagement of the APO-1/Fas pathway. Therefore, the existence of a functional iNOS in B-CLL cells will provide further insights into the mechanisms that control proliferation and apoptosis in these tumor cells. Copyright 1998 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9680373

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

Review 1.  Apoptosis in B-chronic lymphocytic leukaemia.

Authors:  L M Osorio; M Aguilar-Santelises
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

2.  Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.

Authors:  Christine E Eyler; Qiulian Wu; Kenneth Yan; Jennifer M MacSwords; Devin Chandler-Militello; Katherine L Misuraca; Justin D Lathia; Michael T Forrester; Jeongwu Lee; Jonathan S Stamler; Steven A Goldman; Markus Bredel; Roger E McLendon; Andrew E Sloan; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell       Date:  2011-07-08       Impact factor: 41.582

Review 3.  Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.

Authors:  Stéphanie Haiat; Christian Billard; Claire Quiney; Florence Ajchenbaum-Cymbalista; Jean-Pierre Kolb
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

Review 4.  Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.

Authors:  Jihoon Kim; Susan N Thomas
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

5.  NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.

Authors:  Haifeng Zhu; Deeksha Vishwamitra; Choladda V Curry; Roxsan Manshouri; Lixia Diao; Aarish Khan; Hesham M Amin
Journal:  J Pathol       Date:  2013-03-14       Impact factor: 7.996

Review 6.  A multi-targeted approach to suppress tumor-promoting inflammation.

Authors:  Abbas K Samadi; Alan Bilsland; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Anupam Bishayee; Asfar S Azmi; Bal L Lokeshwar; Brendan Grue; Carolina Panis; Chandra S Boosani; Deepak Poudyal; Diana M Stafforini; Dipita Bhakta; Elena Niccolai; Gunjan Guha; H P Vasantha Rupasinghe; Hiromasa Fujii; Kanya Honoki; Kapil Mehta; Katia Aquilano; Leroy Lowe; Lorne J Hofseth; Luigi Ricciardiello; Maria Rosa Ciriolo; Neetu Singh; Richard L Whelan; Rupesh Chaturvedi; S Salman Ashraf; H M C Shantha Kumara; Somaira Nowsheen; Sulma I Mohammed; W Nicol Keith; William G Helferich; Xujuan Yang
Journal:  Semin Cancer Biol       Date:  2015-05-05       Impact factor: 15.707

Review 7.  Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation.

Authors:  J B Weinberg
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

8.  Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma.

Authors:  Y Soini; K Kahlos; A Puhakka; E Lakari; M Säily; P Pääkkö; V Kinnula
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.